Finally, considering the toxicity of rituximab in ALPS patients, causing prolonged hypogammaglobulinemia up to life-long IVIG dependency, the percentage of CD4-CD8-TCRαβ+ Τ-lymphocytes was low [12,14]. This evidence concerns the gene CD8A and autoimmune lymphoproliferative syndrome.